MUC1 as a potential target in anticancer therapies

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 38, Issue 1, 2015, Pages 108-118

  Pillai, Krishna ^a   Pourgholami, Mohammad H ^a   Chua, Terence C ^a   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

antibodies; aptamers; MUC1; oncogenes; therapies; Vaccines

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CARBOHYDRATE VACCINE; DENDRITIC CELL VACCINE; DNA VACCINE; GLYCOPEPTIDE VACCINE; MUCIN 1; MUCIN 1 C; MUCIN 1 N; PEPTIDE VACCINE; PROTEIN SH2; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DIMERIZATION; HUMAN; IMMUNOGENICITY; MOLECULAR DOCKING; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; TANDEM REPEAT; TUMOR GROWTH; TUMOR PROMOTION;

EID: 84964294589     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31828f5a07     Document Type: Review

References (165)

1. Brayman M, Thathiah A, Carson DD. MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reprod Biol Endocrinol. 2004;2:4.
2. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia. 2001;6:339-353.
3. Duraisamy S, Kufe T, Ramasamy S, et al. Evolution of the human MUC1 oncoprotein. Int J Oncol. 2007;31:671-677.
4. Linden SK, Florin TH, McGuckin MA. Mucin dynamics in intestinal bacterial infection. PLoS One. 2008;3:e3952.
5. McAuley JL, Linden SK, Png CW, et al. MUC1 cell surface mucin is a critical element of the mucosal barrier to infection. J Clin Invest. 2007;117:2313-2324.
6. Sakamoto H, Yonezawa S, Utsunomiya T, et al. Mucin antigen expression in gastric carcinomas of young and old adults. Hum Pathol. 1997;28:1056-1065.
7. Sachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin Cancer Res. 2010;70:378-387.
8. Wei X, Xu H, Kufe D. MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell. 2006;21: 295-305.
9. Woo JK, Choi Y, Oh SH, et al. Mucin 1 enhances the tumor angiogenic response by activation of the AKT signaling pathway. Oncogene. 2012;31:2187-2198.
10. Mikami Y, Hisatsune A, Tashiro T, et al. Hypoxia enhances MUC1 expression in a lung adenocarcinoma cell line. Biochem Biophys Res Commun. 2009;379:1060-1065.
11. Fessler SP, Wotkowicz MT, Mahanta SK, et al. MUC1 is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Res Treat. 2009;118:113-124.
12. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
13. Parry S, Silverman HS, McDermott K, et al. Identification of MUC1 proteolytic cleavage sites in vivo. Biochem Biophys Res Commun. 2001;283:715-720.
14. Levitin F, Stern O, Weiss M, et al. The MUC1 SEA module is a self-cleaving domain. J Biol Chem. 2005;280:33374-33386.
15. Ligtenberg MJ, Kruijshaar L, Buijs F, et al. Cell-Associated episialin is a complex containing two proteins derived from a common precursor. J Biol Chem. 1992;267:6171-6177.
16. Macao B, Johansson DG, Hansson GC, et al. Autoproteolysis coupled to protein folding in the SEA domain of the membranebound MUC1 mucin. Nat Struct Mol Biol. 2006;13:71-76.
17. Gendler S, Taylor-Papadimitriou J, Duhig T, et al. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem. 1988;263:12820-12823.
18. Lillehoj EP, Han F, Kim KC. Mutagenesis of a Gly-Ser cleavage site in MUC1 inhibits ectodomain shedding. Biochem Biophys Res Commun. 2003;307:743-749.
19. Kufe D, Inghirami G, Abe M, et al. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma. 1984;3:223-232.
20. Ichige K, Perey L, Vogel CA, et al. Expression of the DF3-P epitope in human ovarian carcinomas. Clin Cancer Res. 1995;1:565-571.
21. Raina D, Kharbanda S, Kufe D. The MUC1 oncoprotein activates the anti-Apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem. 2004;279:20607-20612.
22. Yin L, Huang L, Kufe D. MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J Biol Chem. 2004;279:45721-45727.
23. Li Y, Ren J, Yu W, et al. The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. J Biol Chem. 2001;276: 35239-35242.
24. Schroeder JA, Thompson MC, Gardner MM, et al. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-Activated protein kinase activation in the mouse mammary gland. J Biol Chem. 2001;276:13057-13064.
25. Singh PK, Wen Y, Swanson BJ, et al. Platelet-derived growth factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells. Cancer Res. 2007;67:5201-5210.
26. Ren J, Raina D, Chen W, et al. MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling. Mol Cancer Res. 2006;4:873-883.
27. Li Y, Yu WH, Ren J, et al. Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. Mol Cancer Res. 2003;1:765-775.
28. Kufe DW. Targeting the human MUC1 oncoprotein: a tale of two proteins. Cancer Biol Ther. 2008;7:81-84.
29. Agata N, Ahmad R, Kawano T, et al. MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8. Cancer Res. 2008;68:6136-6144.
30. Yin L, Kharbanda S, Kufe D. Mucin 1 oncoprotein blocks hypoxia-inducible factor 1alpha activation in a survival response to hypoxia. J Biol Chem. 2007;282:257-266.
31. Ramasamy S, Duraisamy S, Barbashov S, et al. The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell. 2007;27:992-1004.
32. Pochampalli MR, el Bejjani RM, Schroeder JA. MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene. 2007;26: 1693-1701.
33. Zhao Q, Guo X, Nash GB, et al. Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. Cancer Res. 2009;69:6799-6806.
34. Wang H, Lillehoj EP, Kim KC. Identification of four sites of stimulated tyrosine phosphorylation in the MUC1 cytoplasmic tail. Biochem Biophys Res Commun. 2003;310: 341-346.
35. Li Y, Kuwahara H, Ren J, et al. The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinomaassociated antigen with GSK3 beta and beta-catenin. J Biol Chem. 2001;276:6061-6064.
36. Li Y, Bharti A, Chen D, et al. Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-Associated antigen and beta-catenin. Mol Cell Biol. 1998;18:7216-7224.
37. Ren J, Li Y, Kufe D. Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. J Biol Chem. 2002;277:17616-17622.
38. Wen Y, Caffrey TC, Wheelock MJ, et al. Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. J Biol Chem. 2003;278:38029-38039.
39. Hattrup CL, Fernandez-Rodriguez J, Schroeder JA, et al. MUC1 can interact with adenomatous polyposis coli in breast cancer. Biochem Biophys Res Commun. 2004;316:364-369.
40. Pandey P, Kharbanda S, Kufe D. Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res. 1995;55:4000-4003.
41. Wei X, Xu H, Kufe D. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell. 2005;7:167-178.
42. Li Y, Kufe D. The human DF3/MUC1 carcinoma-Associated antigen signals nuclear localization of the catenin p120(ctn). Biochem Biophys Res Commun. 2001;281:440-443.
43. Ren J, Bharti A, Raina D, et al. MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90. Oncogene. 2006;25:20-31.
44. Yan TD, Deraco M, Elias D, et al. A novel tumor-nodemetastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer. 2011;117:1855-1863.
45. Meerzaman D, Shapiro PS, Kim KC. Involvement of the MAP kinase ERK2 in MUC1 mucin signaling. Am J Physiol Lung Cell Mol Physiol. 2001;281:L86-L91.
46. Ren J, Agata N, Chen D, et al. Human MUC1 carcinomaassociated protein confers resistance to genotoxic anticancer agents. Cancer Cell. 2004;5:163-175.
47. Yin L, Li Y, Ren J, et al. Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem. 2003;278:35458-35464.
48. Yin L, Wu Z, Avigan D, et al. MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells. Blood. 2011;117:4863-4870.
49. Huang L, Ren J, Chen D, et al. MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. Cancer Biol Ther. 2003;2:702-706.
50. Roy LD, Sahraei M, Subramani DB, et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene. 2011;30:1449-1459.
51. Ahmad R, Alam M, Rajabi H, et al. The MUC1-C oncoprotein binds to the BH3 domain of the pro-Apoptotic BAX protein and blocks BAX function. J Biol Chem. 2012;287:20866-20875.
52. Pitroda SP, Khodarev NN, Beckett MA, et al. MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci U S A. 2009;106:5837-5841.
53. Raina D, Kosugi M, Ahmad R, et al. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther. 2011;10:806-816.
54. Kosugi M, Ahmad R, Alam M, et al. MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells. PLoS One. 2011;6:e28234.
55. Singh R, Bandyopadhyay D. MUC1: a target molecule for cancer therapy. Cancer Biol Ther. 2007;6:481-486.
56. Kufe DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2012;32:1073-1081.
57. Yang E, Hu XF, Xing PX. Advances of MUC1 as a target for breast cancer immunotherapy. Histol Histopathol. 2007;22: 905-922.
58. Yin L, Ahmad R, Kosugi M, et al. Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein. Cancer Biol Ther. 2010;10:483-491.
59. Pegram MD, Borges VF, Ibrahim N, et al. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 2009;11:R73.
60. Ibrahim NK, Yariz KO, Bondarenko I, et al. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clin Cancer Res. 2011;17:6822-6830.
61. Hird V, Maraveyas A, Snook D, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer. 1993;68:403-406.
62. Kosmas C, Epenetos AA, Courtenay-Luck NS. Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer. Cancer. 1994;73:3000-3010.
63. Kalra AV, Campbell RB. Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain. Br J Cancer. 2007;97: 910-918.
64. Zheng P, Sarma S, Guo Y, et al. Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: lessons from recurrent tumors. Cancer Res. 1999;59:3461-3467.
65. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342: 1350-1358.
66. Yang L, Yamagata N, Yadav R, et al. Cancer-Associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest. 2003;111: 727-735.
67. Agrawal B, Krantz MJ, Parker J, et al. Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation. Cancer Res. 1998;58: 4079-4081.
68. Zhang K, Sikut R, Hansson GC. A MUC1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells. Cell Immunol. 1997;176:158-165.
69. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol. 2000;18:574-583.
70. Croce MV, Isla-Larrain MT, Capafons A, et al. Humoral immune response induced by the protein core of MUC1 mucin in pregnant and healthy women. Breast Cancer Res Treat. 2001;69:1-11.
71. Agrawal B, Reddish MA, Krantz MJ, et al. Does pregnancy immunize against breast cancer? Cancer Res. 1995;55: 2257-2261.
72. George SK, Schwientek T, Holm B, et al. Chemoenzymatic synthesis of sialylated glycopeptides derived from mucins and T-cell stimulating peptides. J Am Chem Soc. 2001;123: 11117-11125.
73. Goydos JS, Elder E, Whiteside TL, et al. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res. 1996;63:298-304.
74. Acres B, Apostolopoulos V, Balloul JM, et al. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother. 2000;48:588-594.
75. Loveland BE, Zhao A, White S, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res. 2006;12:869-877.
76. Zinkernagel RM, Doherty PC. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv Immunol. 1979;27:51-177.
77. Xing P, Michael M, Apostolopoulos V, et al. Phase-I study of synthetic muc1 peptides in breast-cancer. Int J Oncol. 1995; 6:1283-1289.
78. Reddish M, MacLean GD, Koganty RR, et al. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer. 1998;76:817-823.
79. Ramanathan RK, Lee KM, McKolanis J, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother. 2005;54: 254-264.
80. Apostolopoulos V, Pietersz GA, Loveland BE, et al. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci U S A. 1995;92: 10128-10132.
81. Karanikas V, Hwang LA, Pearson J, et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest. 1997;100: 2783-2792.
82. Apostolopoulos V, Pietersz GA, Tsibanis A, et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res. 2006;8:R27.
83. Heukamp LC, van der Burg SH, Drijfhout JW, et al. Identification of three non-VNTR MUC1-derived HLA-A0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice. Int J Cancer. 2001;91:385-392.
84. Kohlgraf KG, Gawron AJ, Higashi M, et al. Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1). Cancer Immunol Immunother. 2004;53:1068-1084.
85. Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res. 2007;13:s4652-s4654.
86. Springer GF. T and Tn, general carcinoma autoantigens. Science. 1984;224:1198-1206.
87. MacLean GD, Reddish M, Koganty RR, et al. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus detox adjuvant. Cancer Immunol Immunother. 1993;36: 215-222.
88. Holmberg LA, Sandmaier BM. Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Expert Rev Vaccines. 2004;3:655-663.
89. Sorensen AL, Reis CA, Tarp MA, et al. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology. 2006;16:96-107.
90. von Mensdorff-Pouilly S, Petrakou E, Kenemans P, et al. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-Acetylgalactosamine (GalNAc) peptides. Int J Cancer. 2000;86:702-712.
91. Hanisch FG. Design of a MUC1-based cancer vaccine. Biochem Soc Trans. 2005;33:705-708.
92. Hanisch FG, Schwientek T, Von Bergwelt-Baildon MS, et al. O-Linked glycans control glycoprotein processing by antigenpresenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells. Eur J Immunol. 2003;33:3242-3254.
93. Ragupathi G, Coltart DM, Williams LJ, et al. On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines. Proc Natl Acad Sci U S A. 2002;99:13699-13704.
94. Lakshminarayanan V, Thompson P, Wolfert MA, et al. Immune recognition of tumor-Associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc Natl Acad Sci U S A. 2012;109:261-266.
95. Yannelli JR, Wroblewski JM. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine. 2004; 23:97-113.
96. Fioretti D, Iurescia S, Fazio VM, et al. DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol. 2010;2010:174378.
97. Chaudhuri D, Suriano R, Mittelman A, et al. Targeting the immune system in cancer. Curr Pharm Biotechnol. 2009;10: 166-184.
98. Ferrone CR, Perales MA, Goldberg SM, et al. Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clin Cancer Res. 2006;12:5511-5519.
99. Ruffini PA, Grodeland G, Fredriksen AB, et al. Human chemokine MIP1alpha increases efficiency of targeted DNA fusion vaccines. Vaccine. 2010;29:191-199.
100. Johnen H, Kulbe H, Pecher G. Long-term tumor growth suppression in mice immunized with naked DNA of the human tumor antigen mucin (MUC1). Cancer Immunol Immunother. 2001;50:356-360.
101. Snyder LA, Goletz TJ, Gunn GR, et al. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice. Vaccine. 2006;24:3340-3352.
102. Hiltbold EM, Vlad AM, Ciborowski P, et al. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol. 2000;165:3730-3741.
103. Wu WC, Jin DY, Lou WH, et al. Induction of antigen-specific CTL and antibody responses in mice by a novel recombinant tandem repeat DNA vaccine targeting at mucin 1 of pancreatic cancer. J Cancer Res Clin Oncol. 2010;136: 1861-1868.
104. Rong Y, Jin D, Wu W, et al. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine. BMC Cancer. 2009;9:191.
105. Choi DH, Woo JK, Choi Y, et al. A novel chimeric DNA vaccine: enhancement of preventive and therapeutic efficacy of DNA vaccine by fusion of Mucin 1 to a heat shock protein 70 gene. Mol Med Report. 2011;4:885-890.
106. Choi Y, Jeon YH, Jang JY, et al. Treatment with mANT2 shRNA enhances antitumor therapeutic effects induced by MUC1 DNA vaccination. Mol Ther. 2011;19:979-989.
107. Weng Y, Shao L, Ouyang H, et al. A unique MUC1-2-VNTR DNA vaccine suppresses tumor growth and prolongs survival in a murine multiple myeloma model. Oncol Rep. 2012;27: 1815-1822.
108. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449:419-426.
109. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296-306.
110. Markowicz S, Engleman EG. Granulocyte-macrophage colonystimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest. 1990;85:955-961.
111. Almand B, Resser JR, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000;6:1755-1766.
112. Della Bella S, Gennaro M, Vaccari M, et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer. 2003;89:1463-1472.
113. Gabrilovich DI, Corak J, Ciernik IF, et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res. 1997;3:483-490.
114. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92:4150-4166.
115. Allavena P, Piemonti L, Longoni D, et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol. 1998;28:359-369.
116. Menetrier-Caux C, Montmain G, Dieu MC, et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colonystimulating factor. Blood. 1998;92:4778-4791.
117. Birkle S, Zeng G, Gao L, et al. Role of tumor-Associated gangliosides in cancer progression. Biochimie. 2003;85:455-463.
118. Carlos CA, Dong HF, Howard OM, et al. Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J Immunol. 2005;175:1628-1635.
119. Rughetti A, Pellicciotta I, Biffoni M, et al. Recombinant tumorassociated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J Immunol. 2005;174:7764-7772.
120. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109-1118.
121. Bonifaz L, Bonnyay D, Mahnke K, et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8 + T cell tolerance. J Exp Med. 2002;196:1627-1638.
122. Fong L, Brockstedt D, Benike C, et al. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol. 2001;166:4254-4259.
123. Kontani K, Taguchi O, Ozaki Y, et al. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med. 2003;12:493-502.
124. Tang CK, Katsara M, Apostolopoulos V. Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines. 2008;7:963-975.
125. Lepisto AJ, Moser AJ, Zeh H, et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 2008;6:955-964.
126. Pecher G, Haring A, Kaiser L, et al. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother. 2002;51:669-673.
127. Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res. 2004;10:4699-4708.
128. Kikuchi T, Akasaki Y, Abe T, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother. 2004;27: 452-459.
129. Homma S, Kikuchi T, Ishiji N, et al. Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12. Eur J Clin Invest. 2005;35:279-286.
130. Homma S, Sagawa Y, Ito M, et al. Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses. Clin Exp Immunol. 2006;144:41-47.
131. Kimura Y, Tsukada J, Tomoda T, et al. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas. 2012;41:195-205.
132. Huang L, Chen D, Liu D, et al. MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res. 2005;65: 10413-10422.
133. Ahmad R, Raina D, Joshi MD, et al. MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor. Cancer Res. 2009;69:7013-7021.
134. Khodarev N, Ahmad R, Rajabi H, et al. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene. 2010;29:920-929.
135. Ahmad R, Rajabi H, Kosugi M, et al. MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal. 2011;4:ra9.
136. Joshi MD, Ahmad R, Yin L, et al. MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol Cancer Ther. 2009;8:3056-3065.
137. Raina D, Ahmad R, Joshi MD, et al. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res. 2009;69:5133-5141.
138. Zhou Y, Rajabi H, Kufe D. Mucin 1 C-terminal subunit oncoprotein is a target for small-molecule inhibitors. Mol Pharmacol. 2011;79:886-893.
139. Yin L, Ahmad R, Kosugi M, et al. Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function. Mol Pharmacol. 2010;78:166-174.
140. Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126:107-120.
141. Yin L, Kosugi M, Kufe D. Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH. Blood. 2012;119:810-816.
142. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 2000;41:147-162.
143. Dhar S, Gu FX, Langer R, et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A. 2008; 105:17356-17361.
144. Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticleaptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004;64:7668-7672.
145. Pochampalli MR, Bitler BG, Schroeder JA. Transforming growth factor alpha dependent cancer progression is modulated by Muc1. Cancer Res. 2007;67:6591-6598.
146. Li X, Wang L, Nunes DP, et al. Suppression of MUC1 synthesis downregulates expression of the epidermal growth factor receptor. Cancer Biol Ther. 2005;4:968-973.
147. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, et al. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol. 2008;26:442-449.
148. Brown KC. Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications. Curr Pharm Des. 2010;16:1040-1054.
149. Osborne SE, Matsumura I, Ellington AD. Aptamers as therapeutic and diagnostic reagents: problems and prospects. Curr Opin Chem Biol. 1997;1:5-9.
150. Ferreira CS, Matthews CS, Missailidis S. DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumour Biol. 2006;27:289-301.
151. Savla R, Taratula O, Garbuzenko O, et al. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J Control Release. 2011;153:16-22.
152. Yu C, Hu Y, Duan J, et al. Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS One. 2011;6:e24077.
153. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov. 2010;9:537-550.
154. Karakoti AS, Das S, Thevuthasan S, et al. PEGylated inorganic nanoparticles. Angew Chem Int Ed Engl. 2011;50:1980-1994.
155. Cerchia L, de Franciscis V. Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol. 2010;28:517-525.
156. Micklefield J. Backbone modification of nucleic acids: synthesis, structure and therapeutic applications. Curr Med Chem. 2001;8: 1157-1179.
157. Bell NM, Micklefield J. Chemical modification of oligonucleotides for therapeutic, bioanalytical and other applications. Chembiochem. 2009;10:2691-2703.
158. Bagalkot V, Gao X. siRNA-Aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing. ACS Nano. 2011;5:8131-8139.
159. Kim D, Jeong YY, Jon S. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano. 2010;4:3689-3696.
160. Chang M, Yang CS, Huang DM. Aptamer-conjugated DNA icosahedral nanoparticles as a carrier of doxorubicin for cancer therapy. ACS Nano. 2011;5:6156-6163.
161. Tan L, Gee Neoh K, Kang ET, et al. Designer tridentate mucin 1 aptamer for targeted drug delivery. J Pharm Sci. 2012;101: 1672-1677.
162. Kufe DW. Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther. 2009;8:1197-1203.
163. Schlom J. The MUC1-C oncoprotein as a target in hematologic malignancies. Cancer Biol Ther. 2010;10:492-494.
164. Kalra AV, Campbell RB. Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours. Eur J Cancer. 2009;45:164-173.
165. Ferreira CS, Papamichael K, Guilbault G, et al. DNA aptamers against the MUC1 tumour marker: design of aptamer-Antibody sandwich ELISA for the early diagnosis of epithelial tumours. Anal Bioanal Chem. 2008;390:1039-1050.